Adult Oral 15 g tid-qid. Rectal 30 g given as susp in 100 mL of methylcellulose '450' 2% & water 100 mL retained for at least 9 hr. Initial therapy may involve both oral & rectal routes. Childn Oral Acute hyperkalemia 1 g/kg daily in divided doses. Reduce to a maintenance dose of 500 mg/kg daily in divided doses. Neonates & childn Rectal Similar dose w/ oral dose suggested for childn.
Should be taken on an empty stomach.
Hypersensitivity. Hypercalcemia & ventricular fibrillation. Hyperparathyroidism, mulitple myeloma, sarcoidosis or metastatic carcinoma who may present w/ renal failure w/ hypercalcemia.
Closely monitor electrolytes during therapy & discontinue if K ≤5 mmol/L (5 mEq/L). Renal impairment &/or dialysis patients may have increased Ca levels. Monitor Ca weekly or more frequently. Discontinue use if clinically significant constipation occurs. Avoid Mg-containing laxatives. Concomitant use w/ rectal sorbital.
Constipation & headache. Mild hypercalcemia (Ca >10.5 mg/dL), anorexia, nausea & vomiting. More severe hypercalcemia (Ca >12 mg/dL) associated w/ confusion, delirium, stupor & coma.
May reduce absorption of tetracycline (oral), alendronate, etidronate, ibandronate, risedronate & Fe prep. Arrhythmias may occur w/ cardiac glycosides. May reduce oral bioavailability of fluoroquinolones (eg, ciprofloxacin).